From: Identification of lipidomic profiles associated with drug-resistant prostate cancer cells
Prostate Study | Number of Samples |
---|---|
Prostate Cancer (DKFZ, Cancer Cell 2018) | 324 |
Prostate Cancer (MSK, 2019) | 18 |
Metastatic Prostate Adenocarcinoma (MCTP, Nature 2012) | 61 |
Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019) | 444 |
Metastatic Prostate Cancer (SU2C/PCF Dream Team, Cell 2015) | 150 |
Metastatic castration-sensitive prostate cancer (MSK, Clin Cancer Res 2020) | 424 |
Neuroendocrine Prostate Cancer (Multi-Institute, Nat Med 2016) | 114 |
Prostate Adenocarcinoma (Broad/Cornell, Cell 2013) | 57 |
Prostate Adenocarcinoma (CPC-GENE, Nature 2017) | 477 |
Prostate Adenocarcinoma (MSKCC, 2020) | 1465 |
Prostate Adenocarcinoma (MSKCC, Cancer Cell 2010) | 240 |
Prostate Adenocarcinoma (SMMU, Eur Urol 2017) | 65 |
Prostate Adenocarcinoma (TCGA, Cell 2015) | 333 |
Prostate Adenocarcinoma Organoids (MSKCC, Cancer Cell 2014) | 12 |
Prostate Cancer (MSKCC, JCO Precis Oncol 2017) | 504 |
The Metastatic Prostate Cancer Project (Provisional, November 2019) | 75 |